File Download
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-50949117439
- PMID: 18452145
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen.
Title | Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. |
---|---|
Authors | |
Issue Date | 2008 |
Citation | Hepatology (Baltimore, Md.), 2008, v. 48 n. 2, p. 1-10 How to Cite? |
Abstract | Whether preemptive anti- hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumab containing chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzumab-containing chemotherapy regimen in occult HBV-infected patients. Twenty-one consecutive occult HBV-infected patients treated with an alemtuzumab containing chemotherapy regimen were studied. T cell reactivity to HBV antigens and -peptides were quantified by ELISpot and the T cell subset by flow cytometry. Six of the 21 patients (28.6%) developed HBsAg seroreversion. The median (range) time to development of HBsAg seroreversion after the end of chemotherapy was 1.8 months (0.2-2.3 months). Direct sequencing showed that the occult HBV infection of all six patients (100%) was reactivated. These six patients developed severe HBV-related hepatitis. At the end of follow-up, four of these six patients (66.7%) had become negative for HBsAg again. Recovery of CD4+ T cell count and CD4+T cell reactivity against hepatitis B core antigen (HBcAg) occurred 9 months after the end of chemotherapy. Loss of HBsAg occurred after recovery of the CD4+T cell count and increased CD4+T cell reactivity against HBcAg 9 months after the end of chemotherapy. CONCLUSION: An alemtuzumab-containing chemotherapy regimen is associated with a high risk of reactivation of occult HBV infection. Suppression of HBV immunity by an alemtuzumab-containing chemotherapy regimen would persist until 9 months after the end of chemotherapy. In occult HBV-infected patients receiving an alemtuzumab-containing chemotherapy regimen, preemptive anti-HBV therapy should be continued until 9 months after the end of chemotherapy, when recovery of HBV immunity has occurred. |
Persistent Identifier | http://hdl.handle.net/10722/163198 |
ISSN | 2023 Impact Factor: 12.9 2023 SCImago Journal Rankings: 5.011 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hui, CK | en_US |
dc.contributor.author | Cheung, WW | en_US |
dc.contributor.author | Leung, KW | en_US |
dc.contributor.author | Cheng, VCC | en_US |
dc.contributor.author | Tang, BSF | en_US |
dc.contributor.author | Li, IWS | en_US |
dc.contributor.author | Luk, JM | en_US |
dc.contributor.author | Lee, NP | en_US |
dc.contributor.author | Kwong, YL | en_US |
dc.contributor.author | Au, WY | en_US |
dc.contributor.author | Yuen, KY | en_US |
dc.contributor.author | Lau, GK | en_US |
dc.contributor.author | Liang, R | en_US |
dc.date.accessioned | 2012-09-05T05:28:40Z | - |
dc.date.available | 2012-09-05T05:28:40Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | Hepatology (Baltimore, Md.), 2008, v. 48 n. 2, p. 1-10 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163198 | - |
dc.description.abstract | Whether preemptive anti- hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumab containing chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzumab-containing chemotherapy regimen in occult HBV-infected patients. Twenty-one consecutive occult HBV-infected patients treated with an alemtuzumab containing chemotherapy regimen were studied. T cell reactivity to HBV antigens and -peptides were quantified by ELISpot and the T cell subset by flow cytometry. Six of the 21 patients (28.6%) developed HBsAg seroreversion. The median (range) time to development of HBsAg seroreversion after the end of chemotherapy was 1.8 months (0.2-2.3 months). Direct sequencing showed that the occult HBV infection of all six patients (100%) was reactivated. These six patients developed severe HBV-related hepatitis. At the end of follow-up, four of these six patients (66.7%) had become negative for HBsAg again. Recovery of CD4+ T cell count and CD4+T cell reactivity against hepatitis B core antigen (HBcAg) occurred 9 months after the end of chemotherapy. Loss of HBsAg occurred after recovery of the CD4+T cell count and increased CD4+T cell reactivity against HBcAg 9 months after the end of chemotherapy. CONCLUSION: An alemtuzumab-containing chemotherapy regimen is associated with a high risk of reactivation of occult HBV infection. Suppression of HBV immunity by an alemtuzumab-containing chemotherapy regimen would persist until 9 months after the end of chemotherapy. In occult HBV-infected patients receiving an alemtuzumab-containing chemotherapy regimen, preemptive anti-HBV therapy should be continued until 9 months after the end of chemotherapy, when recovery of HBV immunity has occurred. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Hepatology (Baltimore, Md.) | en_US |
dc.rights | Hepatology. Copyright © John Wiley & Sons, Inc. | - |
dc.title | Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. | en_US |
dc.type | Article | en_US |
dc.identifier.email | Luk, JM:jmluk@hkucc.hku.hk | en_US |
dc.identifier.email | Lee, NP:nikkilee@hku.hk | en_US |
dc.identifier.email | Kwong, YL:ylkwong@hku.hk | en_US |
dc.identifier.email | Yuen, KY:kyyuen@hkucc.hku.hk | en_US |
dc.identifier.email | Liang, R:rliang@hku.hk | en_US |
dc.identifier.authority | Luk, JM=rp00349 | en_US |
dc.identifier.authority | Lee, NP=rp00263 | en_US |
dc.identifier.authority | Kwong, YL=rp00358 | en_US |
dc.identifier.authority | Yuen, KY=rp00366 | en_US |
dc.identifier.authority | Liang, R=rp00345 | en_US |
dc.description.nature | link_to_OA_fulltext | en_US |
dc.identifier.pmid | 18452145 | en_US |
dc.identifier.scopus | eid_2-s2.0-50949117439 | en_US |
dc.identifier.hkuros | 145637 | - |
dc.identifier.volume | 48 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 1 | en_US |
dc.identifier.epage | 10 | en_US |
dc.identifier.scopusauthorid | Hui, CK=7202876933 | en_US |
dc.identifier.scopusauthorid | Cheung, WW=8615134400 | en_US |
dc.identifier.scopusauthorid | Leung, KW=23097859100 | en_US |
dc.identifier.scopusauthorid | Cheng, VC=23670479400 | en_US |
dc.identifier.scopusauthorid | Tang, BS=8908243000 | en_US |
dc.identifier.scopusauthorid | Li, IW=24464179500 | en_US |
dc.identifier.scopusauthorid | Luk, JM=7006777791 | en_US |
dc.identifier.scopusauthorid | Lee, NP=7402722690 | en_US |
dc.identifier.scopusauthorid | Kwong, YL=7102818954 | en_US |
dc.identifier.scopusauthorid | Au, WY=7202383089 | en_US |
dc.identifier.scopusauthorid | Yuen, KY=36078079100 | en_US |
dc.identifier.scopusauthorid | Lau, GK=7102301257 | en_US |
dc.identifier.scopusauthorid | Liang, R=26643224900 | en_US |
dc.customcontrol.immutable | jt 130625 | - |
dc.identifier.issnl | 0270-9139 | - |